Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003432 · ClinicalTrials.gov registry record · Phase 1
Immunotherapy in Treating Patients With Metastatic Breast Cancer
A Phase 1 study, sponsored by Duke University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT00003432: Clinical Trial Phase 1 study, sponsored by Duke University.
NCT00003432 is a Phase 1 study that was terminated before completion, run by Duke University. The registered enrollment target is 4 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003432, a Phase 1 study, was terminated before completion, sponsored by Duke University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
RATIONALE: Immunotherapy using CEA-treated white blood cells may help a person's body build an immune response to and kill their tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of immunotherapy with CEA-treated white blood cells in treating patients with metastatic breast cancer who have achieved a partial or complete response after chemotherapy and peripheral stem cell transplantation.
Interventions
- BIOLOGICAL carcinoembryonic antigen RNA-pulsed DC cancer vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 1998-06 |
| Est. Completion | 2002-11 |
| Phase | Phase 1 |
Why NCT00003432 stopped before completion
NCT00003432 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 1 intervention - of which carcinoembryonic antigen RNA-pulsed DC cancer vaccine is the first listed.
NCT00003432 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00003432 about?
NCT00003432 is a clinical study titled "Immunotherapy in Treating Patients With Metastatic Breast Cancer". RATIONALE: Immunotherapy using CEA-treated white blood cells may help a person's body build an immune response to and kill their tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of immunotherapy with CEA-treated white blood cells in treating patients with metastatic breast cancer w...
What is the current status of trial NCT00003432?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 1998-06. Estimated completion is 2002-11.
What interventions are being tested in trial NCT00003432?
The interventions under investigation include: carcinoembryonic antigen RNA-pulsed DC cancer vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003432?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00003432's enrollment target sits among peer trials
4 1995th of 2000 higher than 2 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia